9月30日，南新制药（维权）公告，公司收到中国证监会出具的《立案告知书》，因公司涉嫌年报信息 披露违法违规，证监会决定对公司立案。 证监会的立案调查，直指公司年报信息披露涉嫌违法违规。随后公司股价大幅下跌，致使不少投资者遭 受亏损。 登录新浪财经APP 搜索【信披】查看更多考评等级 一、仍处监管立案调查 上海沪紫律师事务所刘鹏律师团队截止目前已收到上百位投资者的索赔报名，并于近日递交至法院立 案。（刘鹏律师专栏） 受损投资者可积极参与维权，尽可能挽回损失。投资者只需提供相关交易记录、身份证明等材料，便可 进行报名登记。律师团队有着丰富的证券维权经验，此前已成功代理多起类似案件，为众多投资者挽回 了经济损失。 （本文由上海沪紫律师事务所刘鹏律师供稿，不代表新浪财经的观点。刘鹏律师，专注证券维权19年， 自2006年执业以来，成功为中青宝、国华网安、劲嘉股份（维权）等 300 余家上市公司的中小投资者成 功维权，案件在办数量超过 14000 起，胜诉率达 99.2%。作为业内资深证券维权律师，刘鹏律师精准把 握案件核心，诉讼经验丰富，索赔策略高效，为投资者争取最大权益，维权实力行业领先。证券维权， 选对律师是关键 ...

中国经济网北京12月4日讯 南新制药(688189.SH)今日收报8.78元，跌幅5.69%，总市值24.09亿元。 目前该股处于破发状态。 2023年6月7日，公司披露2022年年度权益分派实施公告，以方案实施前的公司总股本196,000,000股 为基数，以资本公积金向全体股东每股转增0.4股，共计转增78,400,000股，本次分配后总股本为 274,400,000股。股权登记日为2023年6月12日，除权（息）日为2023年6月13日。 （责任编辑：田云绯） 南新制药首次公开发行股票募集资金总额为12.23亿元，募集资金净额为11.35亿元，比原拟募集资 金多4.66亿元。南新制药2020年3月20日招股书显示，该公司原拟募集资金6.70亿元，分别用于创新药研 发项目、营销渠道网络升级建设项目、补充流动资金。 南新制药首次公开发行股票的发行费用总计为8761.77万元（不含增值税），其中，西部证券股份 有限公司获得保荐及承销费用合计7110.75万元（不含增值税）。 2022年7月16日，南新制药披露2021年年度权益分派实施公告，以方案实施前的公司总股本 140,000,000股为基数，以资本公积金 ...

Group 1 - The total amount of share buybacks by A-share listed companies has exceeded 130 billion yuan this year, marking the second highest level in history [1][2] - In December, several companies from Hunan Province, including Hualing Steel and Blue思科技, have announced their share buyback progress, with a total buyback amount exceeding 800 million yuan [1] - Century Huatong completed its share buyback with a total amount of approximately 999.9 million yuan, repurchasing 56,120,796 shares at prices ranging from 17.06 yuan to 18.38 yuan per share [1] Group 2 - Over 1,400 companies in the A-share market have implemented buybacks since 2025, with the total buyback amount exceeding 130 billion yuan [2] - Midea Group leads the buyback amounts this year with over 9.6 billion yuan, having announced two buyback plans [2] - The stock buyback index has increased by over 27% this year, reaching a historical high, with more than 100 companies doubling their stock prices [2] Group 3 - As of December 2, Blue思科技 has repurchased 7.31 million shares for a total amount of 212 million yuan [3] - Flag Group has repurchased 27.96 million shares, exceeding its planned buyback amount, with a total buyback amount of 196 million yuan [3] - Hunan Silver has repurchased 19.76 million shares, with a total buyback amount of 106 million yuan [3] Group 4 - As of November 30, Hualing Steel has repurchased 4.35 million shares for a total amount of 210 million yuan [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 截至2025年11月30日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份 958,020股，占公司总股本274,400,000股的比例为0.35%，回购成交的最高价为8.92元/股，最低价为7.02 元/股，支付的资金总额为人民币7,997,847.83元（不含印花税、交易佣金等交易费用）。 上述股份回购符合法律法规的规定及公司回购股份方案的要求。 重要内容提示： ■ 一、回购股份的基本情况 湖南南新制药股份有限公司（以下简称"公司"）于2025年4月28日召开第二届董事会第十五次会议，审 议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司以不低于人民币1,000万元 （含）且不超过人民币2,000万元（含）的自有资金或自筹资金，通过集中竞价交易方式回购公司人民 币普通股（A股）股票，用于实施股权激励或员工持股计划，回购价格不超过人民币9.53元/股（含）， 回购期限为自公司董事会审议通过本次回购股份方案之日起12个月内。具体情况详见公司于2025年4月 30日在上海证券交易所网站（www.sse.com.cn）披露的《关于 ...

每经AI快讯，南新制药（SH 688189，收盘价：9.28元）12月1日晚间发布公告称，截至2025年11月30 日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份约96万股，占公司总股本 约2.74亿股的比例为0.35%，回购成交的最高价为8.92元/股，最低价为7.02元/股，支付的资金总额为人 民币约800万元。 2024年1至12月份，南新制药的营业收入构成为：医药制造占比99.99%，其他业务占比0.01%。 （记者 王晓波） 截至发稿，南新制药市值为25亿元。 每经头条（nbdtoutiao）——5年期大面积下线，3年期利率低至1.5%仍一单难求：要么"售罄"要么"额度 紧张"！中长期大额存单为何在消失？ ...

证券代码：688189 证券简称：南新制药 公告编号：2025-052 湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 958,020股 | | 累计已回购股数占总股本比例 | 0.35% | | 累计已回购金额 | 7,997,847.83元 | | 实际回购价格区间 | 7.02元/股~8.92元/股 | 特此公告。 湖南南新制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第 二届董事会第十五次会议，审议通过了《关于以集中竞价交易方式回购公司股 ...

格隆汇12月1日丨南新制药（维权）(688189.SH)公布，截至2025年11月30日，公司通过上海证券交易所 交易系统以集中竞价交易方式累计回购公司股份958,020股，占公司总股本的比例为0.35%，回购成交的 最高价为8.92元/股，最低价为7.02元/股，支付的资金总额为人民币799.78万元（不含印花税、交易佣金 等交易费用）。 ...

Core Viewpoint - Nanjing Pharmaceutical has faced significant setbacks due to regulatory penalties and ongoing investigations, leading to continued financial losses and a volatile stock performance [1] Financial Performance - Nanjing Pharmaceutical has reported net losses for four consecutive years since 2021, with a loss of 0.69 billion yuan in the first three quarters of this year [1] - Despite a brief surge in stock price due to restructuring expectations, the stock has since halved from its peak earlier this year, although it remains up over 40% year-to-date [1] Regulatory Issues - The Ministry of Finance has imposed a fine of 100,000 yuan on Nanjing Pharmaceutical for inflating revenue by over 24 million yuan through fraudulent shipping documents and misreporting academic promotion expenses of 37 million yuan [1] - The company's head, Zhang Shixi, has also been fined 50,000 yuan for his responsibility in these violations [1] - Additionally, the China Securities Regulatory Commission has initiated an investigation into the company's annual report disclosure violations [1]

Core Viewpoint - The A-share market experienced a significant rally on November 25, with the ChiNext Index rising nearly 2%, driven by a surge in flu-related stocks due to an increase in flu activity across the country [1] Group 1: Market Performance - The ChiNext Index saw a nearly 2% increase on November 25, indicating strong market performance [1] - Flu-related stocks, such as Jindike and Xinhua Pharmaceutical, reached their daily limit up, reflecting heightened investor interest [1] Group 2: Flu Activity and Sales Data - National flu activity has rapidly increased in November, with Beijing entering a high incidence period for respiratory infectious diseases [1] - Sales of Oseltamivir surged by 237% over the past week, while sales of Maviral (Sofosbuvir) increased by 180% [1] - Data from Meituan indicates that special flu medications in Beijing have seen a month-on-month growth exceeding 130%, with Maviral growing over 110% and Oseltamivir granules increasing by over 85% [1] Group 3: Investment Opportunities - According to Everbright Securities, the rising flu epidemic is likely to increase public and market attention, leading to a growth in demand for flu prevention and treatment products [1] - Investment opportunities are suggested in flu vaccines, virus testing, cold medications, and special antiviral drugs, as well as blood products as a response to complex epidemic situations [1]

Group 1 - The demand for flu-related medications is rising significantly as the flu season approaches, with several stocks in the sector experiencing price surges [1] - Notable stocks that have reached their daily limit include Jindike, Peking University Medicine, and Te Yi Pharmaceutical, among others [1] - Data from Alibaba Health indicates a more than 500% week-on-week increase in the number of people purchasing antiviral flu medications, with Mabalosavir showing a remarkable over 600% increase [1] Group 2 - Experts warn that the H3N2 strain circulating this year is different from previous years, leading to lower immunity in the population and increased transmission risk [2] - The flu virus is known to undergo antigenic drift, but current strains are still within seasonal levels and do not indicate a stronger evolution of the virus [2] Group 3 - Companies are actively ensuring the supply of flu medications and vaccines in response to rising demand [3] - Dongyang Sunshine, a major supplier of Oseltamivir, reports comprehensive coverage of its products across hospitals, pharmacies, and online platforms, maintaining sufficient inventory [3] - Hualan Biological has noted a significant increase in demand for flu vaccines since October, with plans to enhance market supply and ensure timely delivery through cold chain logistics [3]